Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure

Summary

This randomized controlled trial evaluates whether oral N-acetylcysteine (NAC), given alongside standard supportive care, improves survival and reduces mortality in patients with non-acetaminophen-induced acute liver failure (ALF), compared to supportive care alone. Secondary objectives are to assess NAC's effect on length of hospital stay and improvement in liver function tests. Sixty-two adult patients (18-60 years) will be randomized 1:1 to NAC or control, with outcomes assessed at 28 days (survival/mortality) and day 4 (liver function tests).

Eligibility

Inclusion Criteria:

* Male or female, aged 18-60 years
* Diagnosed with non-acetaminophen- induced acute hepatic failure (per operational definition/EASL criteria)
* Etiology other than acetaminophen overdose (viral hepatitis HAV/HBV/HEV, non-acetaminophen drug-induced liver injury, or idiopathic)
* No NAC treatment received for current episode prior to enrollment

Exclusion Criteria:

* History of chronic liver disease or cirrhosis
* Prior severe cardiac, renal, neurological, or infectious disease that could confound outcomes
* Prior liver transplant or current transplant candidacy
* Known allergy/contraindication to NAC
* Pregnant women.

Conditions2

Interventions1

Related trials

• The ACTS Trial: N-acetylcysteine (NAC) and Night-splinting as a Non-operative Treatment for Carpal Tunnel Syndrome — Emily Krauss
• The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients — Cairo University
• Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT — University of California, Irvine

Browse More Trials